Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 13
2012 19
2013 22
2014 31
2015 28
2016 14
2017 18
2018 18
2019 22
2020 25
2021 22
2022 34
2023 31
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

279 results

Results by year

Filters applied: . Clear all
Page 1
Effects of Bardoxolone Methyl in Alport Syndrome.
Warady BA, Pergola PE, Agarwal R, Andreoli S, Appel GB, Bangalore S, Block GA, Chapman AB, Chin MP, Gibson KL, Goldsberry A, Iijima K, Inker LA, Kashtan CE, Knebelmann B, Mariani LH, Meyer CJ, Nozu K, O'Grady M, Rheault MN, Silva AL, Stenvinkel P, Torra R, Chertow GM. Warady BA, et al. Clin J Am Soc Nephrol. 2022 Dec;17(12):1763-1774. doi: 10.2215/CJN.02400222. Epub 2022 Nov 21. Clin J Am Soc Nephrol. 2022. PMID: 36411058 Free PMC article. Clinical Trial.
BACKGROUND AND OBJECTIVES: Alport syndrome is an inherited disease characterized by progressive loss of kidney function. We aimed to evaluate the safety and efficacy of bardoxolone methyl in patients with Alport syndrome. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: …
BACKGROUND AND OBJECTIVES: Alport syndrome is an inherited disease characterized by progressive loss of kidney function. We aimed to evaluat …
Treatment of Diabetic Kidney Disease: Current and Future.
Yamazaki T, Mimura I, Tanaka T, Nangaku M. Yamazaki T, et al. Diabetes Metab J. 2021 Jan;45(1):11-26. doi: 10.4093/dmj.2020.0217. Epub 2021 Jan 22. Diabetes Metab J. 2021. PMID: 33508907 Free PMC article. Review.
Furthermore, NF-E2-related factor 2 activators improved the glomerular filtration rate of DKD patients in Bardoxolone Methyl Treatment: Renal Function in chronic kidney disease/Type 2 Diabetes (BEAM) trial and Phase II Study of Bardoxolone Methyl in Patients with Ch …
Furthermore, NF-E2-related factor 2 activators improved the glomerular filtration rate of DKD patients in Bardoxolone Methyl Treatmen …
Novel Therapies for Alport Syndrome.
Chavez E, Rodriguez J, Drexler Y, Fornoni A. Chavez E, et al. Front Med (Lausanne). 2022 Apr 25;9:848389. doi: 10.3389/fmed.2022.848389. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35547199 Free PMC article. Review.
We will provide a brief overview of novel therapeutic targets to prevent progression of kidney disease in AS. Our review will include bardoxolone methyl, an oral NRf2 activator; lademirsen, an anti-miRNA-21 molecule; sparsentan, dual endothelin type A receptor (ETAR) and a …
We will provide a brief overview of novel therapeutic targets to prevent progression of kidney disease in AS. Our review will include bar …
A review of clinical characteristics and genetic backgrounds in Alport syndrome.
Nozu K, Nakanishi K, Abe Y, Udagawa T, Okada S, Okamoto T, Kaito H, Kanemoto K, Kobayashi A, Tanaka E, Tanaka K, Hama T, Fujimaru R, Miwa S, Yamamura T, Yamamura N, Horinouchi T, Minamikawa S, Nagata M, Iijima K. Nozu K, et al. Clin Exp Nephrol. 2019 Feb;23(2):158-168. doi: 10.1007/s10157-018-1629-4. Epub 2018 Aug 20. Clin Exp Nephrol. 2019. PMID: 30128941 Free PMC article. Review.
Modelling viral encephalitis caused by herpes simplex virus 1 infection in cerebral organoids.
Rybak-Wolf A, Wyler E, Pentimalli TM, Legnini I, Oliveras Martinez A, Glažar P, Loewa A, Kim SJ, Kaufer BB, Woehler A, Landthaler M, Rajewsky N. Rybak-Wolf A, et al. Nat Microbiol. 2023 Jul;8(7):1252-1266. doi: 10.1038/s41564-023-01405-y. Epub 2023 Jun 22. Nat Microbiol. 2023. PMID: 37349587 Free PMC article.
Combination of anti-inflammatory drugs such as necrostatin-1 or bardoxolone methyl with antiviral treatment prevented the damages caused by infection, indicating that tuning the inflammatory response in acute infection may improve current therapeutic strategies....
Combination of anti-inflammatory drugs such as necrostatin-1 or bardoxolone methyl with antiviral treatment prevented the damages cau …
Oxidative Stress and NRF2/KEAP1/ARE Pathway in Diabetic Kidney Disease (DKD): New Perspectives.
Tanase DM, Gosav EM, Anton MI, Floria M, Seritean Isac PN, Hurjui LL, Tarniceriu CC, Costea CF, Ciocoiu M, Rezus C. Tanase DM, et al. Biomolecules. 2022 Sep 2;12(9):1227. doi: 10.3390/biom12091227. Biomolecules. 2022. PMID: 36139066 Free PMC article. Review.
Hitherto, a wide spectrum of pre-clinical and clinical studies shows the beneficial use of NRF2-inducing strategies, such as NRF2 activators (e.g., Bardoxolone methyl, Curcumin, Sulforaphane and their analogues), and other natural compounds with antioxidant properties in D …
Hitherto, a wide spectrum of pre-clinical and clinical studies shows the beneficial use of NRF2-inducing strategies, such as NRF2 activators …
Bardoxolone-the Phoenix?
Toto RD. Toto RD. J Am Soc Nephrol. 2018 Feb;29(2):360-361. doi: 10.1681/ASN.2017121317. Epub 2018 Jan 25. J Am Soc Nephrol. 2018. PMID: 29371416 Free PMC article. No abstract available.
Bardoxolone methyl: drug development for diabetic kidney disease.
Kanda H, Yamawaki K. Kanda H, et al. Clin Exp Nephrol. 2020 Oct;24(10):857-864. doi: 10.1007/s10157-020-01917-5. Epub 2020 Jun 27. Clin Exp Nephrol. 2020. PMID: 32594372 Free PMC article. Review.
Bardoxolone methyl activates the Keap1/Nrf2 system that plays an important role in defense responses against oxidative stress. Importantly, bardoxolone methyl has demonstrated increases in estimated glomerular filtration rate (eGFR) in patients with diabetic kidney …
Bardoxolone methyl activates the Keap1/Nrf2 system that plays an important role in defense responses against oxidative stress. Import …
Alport Syndrome: A Comprehensive Review on Genetics, Pathophysiology, Histology, Clinical and Therapeutic Perspectives.
Pedrosa AL, Bitencourt L, Paranhos RM, Leitáo CA, Ferreira GC, Simões E Silva AC. Pedrosa AL, et al. Curr Med Chem. 2021;28(27):5602-5624. doi: 10.2174/0929867328666210108113500. Curr Med Chem. 2021. PMID: 33423643 Review.
Novel therapeutic targets under pre-clinical investigation included paricalcitol, sodium-glucose co-transporter- 2 inhibitors, bardoxolone methyl, anti-microRNA-21 oligonucleotides, recombinant human pentraxin-2, lysyl oxidase-like-2 blockers, hydroxypropyl-b-cyclodextrin, …
Novel therapeutic targets under pre-clinical investigation included paricalcitol, sodium-glucose co-transporter- 2 inhibitors, bardoxolon …
Complementary gene regulation by NRF1 and NRF2 protects against hepatic cholesterol overload.
Akl MG, Li L, Baccetto R, Phanse S, Zhang Q, Trites MJ, McDonald S, Aoki H, Babu M, Widenmaier SB. Akl MG, et al. Cell Rep. 2023 Apr 25;42(4):112399. doi: 10.1016/j.celrep.2023.112399. Epub 2023 Apr 14. Cell Rep. 2023. PMID: 37060561 Free article.
Combined deficiency, but not deficiency of either alone, results in severe steatohepatitis, hepatic cholesterol overload and crystallization, altered bile acid metabolism, and decreased biliary cholesterol. Moreover, therapeutic effects of NRF2-activating drug bardoxolone …
Combined deficiency, but not deficiency of either alone, results in severe steatohepatitis, hepatic cholesterol overload and crystallization …
279 results